Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Volume 9 Supplement 2

AIDS Vaccine 2012

Poster presentation | Open | Published:

Development of a novel simian adenovirus 24 based vaccine vector


Human adenovirus serotype 5 is a potent vaccine vector, but its use has been hampered by high seroprevalence amongst people in sub-Sahara Africa. Novel adenoviral vaccine vectors from strains with lower seroprevalence worldwide are being developed that can evade pre-existing immunity. Here we describe the development of a simian Ad24 (sAd24)-based vaccine vector.


Neutralizing antibodies against sAd24 were determined using a panel of 106 rhesus macaque sera and 128 human sera from Rwanda and South Africa using a luciferase-based adenovirus neutralization assay.

The immunogenicity of a single dose of 10E7, 10E8 or 10E9 virus particles of sAd24-SIV Gag based vector was determined in C57BL/6 mice. SIV-Gag-specific immune responses were assessed by Db/AL11 tetramer binding assays, IFN-γ ELISPOT assays and ICS assays.


Neutralizing antibodies were found in 7% of monkeys, all with titers <200. In humans from sub-Saharan Africa, 45% was positive for sAd24 neutralizing antibodies, but titers remained low and 90% had titers <200. In comparison, seroprevalence of Ad5 in sub-Saharan Africa is 86.4-89.5% with 61.1-78.7% of this population showing titers >200 and 25.1-46.8% showing titers >1000. Gag specific cellular immune responses elicited by sAd24-SIV Gag in mice are comparable to those seen with the human Ad26 and Ad28 vectors currently in development.


These data suggest that sAd24 is promising for further studies as a candidate vaccine vector.

Author information

Correspondence to P Abbink.

Rights and permissions

Reprints and Permissions

About this article


  • ELISPOT Assay
  • Neutralization Assay
  • High Seroprevalence
  • Human Adenovirus
  • Vaccine Vector